Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Angelica Petrillo; Elizabeth C. Smyth; Hanneke W. M. van Laarhoven

doi:10.1177/17588359231173177

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Angelica Petrillo^*
, Elizabeth C. Smyth
, Hanneke W. M. van Laarhoven

^*Corresponding author for this work

Ospedale Del Mare
Cambridge University Hospitals NHS Foundation Trust
Amsterdam UMC
University of Amsterdam

Research output: Contribution to journal › Review article › Academic › peer-review

38 Downloads (Pure)

Abstract

Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.

Original language	English
Journal	Therapeutic advances in medical oncology
Volume	15
DOIs	https://doi.org/10.1177/17588359231173177
Publication status	Published - 1 Jan 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

CAR-T cell
Claudin 18.2
FGFR
SPEAR-T
target therapy
trastuzumab deruxtecan

Access to Document

10.1177/17588359231173177

Emerging-targets-in-gastroesophageal-adenocarcinoma.pdfFinal published version, 547 KB

Cite this

@article{b23eb63f04fc4752acc0a9e137b85565,

title = "Emerging targets in gastroesophageal adenocarcinoma: what the future looks like",

abstract = "Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.",

keywords = "CAR-T cell, Claudin 18.2, FGFR, SPEAR-T, target therapy, trastuzumab deruxtecan",

author = "Angelica Petrillo and Smyth, \{Elizabeth C.\} and \{van Laarhoven\}, \{Hanneke W. M.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1177/17588359231173177",

language = "English",

volume = "15",

journal = "Therapeutic advances in medical oncology",

issn = "1758-8340",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Emerging targets in gastroesophageal adenocarcinoma

T2 - what the future looks like

AU - Petrillo, Angelica

AU - Smyth, Elizabeth C.

AU - van Laarhoven, Hanneke W. M.

N1 - Publisher Copyright: © The Author(s), 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.

AB - Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.

KW - CAR-T cell

KW - Claudin 18.2

KW - FGFR

KW - SPEAR-T

KW - target therapy

KW - trastuzumab deruxtecan

UR - https://www.scopus.com/pages/publications/85159107134

U2 - 10.1177/17588359231173177

DO - 10.1177/17588359231173177

M3 - Review article

C2 - 37197225

SN - 1758-8340

VL - 15

JO - Therapeutic advances in medical oncology

JF - Therapeutic advances in medical oncology

ER -

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this